Abelacimab showed a 60-70% reduction in bleeding events compared to rivaroxaban, leading to early trial termination. The trial's results suggest abelacimab could shift the standard of care by ...

The OCEANIC-AF trial has raised concerns about factor XI inhibitors. Should physicians still bet on this class of ...

Favorable bleeding outcomes related to abelacimab have positioned the medication as a potential game changer in the treatment of atrial fibrillation. One of the core results from AZALEA-TIMI 71 ...

We recently compiled a list of the 11 Best Undervalued Stocks to Invest in Now. In this article, we are going to take a look at where Novartis AG (NYSE:NVS) stands against the other undervalued stocks ...

Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 ...

The acquisition represents a homecoming for Anthos’s main asset, abelacimab, a drug that originated in Novartis’s labs. Anthos launched in 2019 with $250 million from Blackstone Life Sciences ...

In this article, we will look at the 11 Best Undervalued Stocks to Invest in Now.

In 2023, Roche said it was removing TNKase for stroke from its phase 3 programmes after a readout of the TIMELESS trial, but ...

Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathwayAbelacimab is currently in ...

The deal is expected to close in H1 2025. Anthos’ abelacimab showed reduced bleeding risks in Phase 2 trials and is in three Phase 3 studies for clot prevention. Every week, our Whisper Index ...

Warfarin was associated with more risk than apixaban (Eliquis; 55.38 vs 21.42 per 1,000 person-years, HR 2.60, 95% CI ...